Revelieria groehni — a New Species of Minute Brown Scavenger Beetles (Coleoptera, Latridiidae) from Baltic Amber

Based on a fossil specimen from Late Eocene Baltic amber, Revelieria groehni Sergi, Perkovsky et Reike, sp. n., a new species is described. It is the first fossil species of the genus Revelieria Perris, 1869. The new species clearly differs from extant R. californica and R. genei in the following characters: eyes more large and convex; antennal insertion located more close to eye; temples very short; metasternum longer; fore tibia evenly curved inwards.Из позднеэоценового балтийского янтаря описан Revelieria groehni Sergi, Perkovsky et Reike, sp. n. Это первый ископаемый вид рода Revelieria Perris, 1869. Новый вид отличается от современных R. californica и R. genei следующими признаками: глаза более крупные и выпуклые; усиковые впадины расположены ближе к глазу; виски очень короткие; заднегрудка длиннее; передняя голень равномерно изогнута внутрь

Chemical Synthesis of Nanostructured Cobalt at Elevated Temperatures

Chemical synthesis is a versatile technique for fabricating novel nanostructured materials. In the Rieke process, a metal salt is reduced by an alkali in a hydrocarbon solvent to form small, highly reactive particles. Synthesis at an elevated temperature (200°C) increases the as-synthesized particle size and produces higher coercivities and remanence ratios than observed in similar syntheses at room temperature. The ratio of synthesis temperature to solvent boiling point appears to be an important parameter in both coercivity and oxidation resistance

Chemical Synthesis of Nanostructured Cobalt at Elevated Temperatures

Chemical synthesis is a versatile technique for fabricating novel nanostructured materials. In the Rieke process, a metal salt is reduced by an alkali in a hydrocarbon solvent to form small, highly reactive particles. Synthesis at an elevated temperature (200°C) increases the as-synthesized particle size and produces higher coercivities and remanence ratios than observed in similar syntheses at room temperature. The ratio of synthesis temperature to solvent boiling point appears to be an important parameter in both coercivity and oxidation resistance

Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer

<p>Abstract</p> <p>Background</p> <p>The incidence of thyroid cancer and the number of patients who die from this disease are increasing globally. Differentiated thyroid cancer (DTC) is the histologic subtype present in most patients and is primarily responsible for the increased overall incidence of thyroid cancer. Sorafenib is a multikinase inhibitor that targets several molecular signals believed to be involved in the pathogenesis of thyroid cancer, including those implicated in DTC. In phase II studies of patients with DTC, sorafenib treatment has yielded a median progression-free survival (PFS) of 58 to 84 weeks and disease control rates of 59% to 100%. The DECISION trial was designed to assess the ability of sorafenib to improve PFS in patients with locally advanced or metastatic, radioactive iodine (RAI)-refractory DTC.</p> <p>Methods/design</p> <p>DECISION is a multicenter, double-blind, randomized, placebo-controlled phase III study in patients with locally advanced/metastatic RAI<b>-</b>refractory DTC. Study treatment will continue until radiographically documented disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent. Efficacy will be evaluated every 56 days (2 cycles), whereas safety will be evaluated every 28 days (1 cycle) for the first 8 months and every 56 days thereafter. Following disease progression, patients may continue or start sorafenib, depending on whether they were randomized to receive sorafenib or placebo, at investigator discretion. Patients originally randomized to receive sorafenib will be followed up every 3 months for overall survival (OS); patients originally randomized to receive placebo will be followed up every month for 8 months after cross-over to sorafenib. The duration of the trial is expected to be 30 months from the time the first patient is randomized until the planned number of PFS events is attained. The primary endpoint is PFS; secondary endpoints include OS, time to disease progression, disease control rate, response rate, duration of response, safety, and pharmacokinetic analysis.</p> <p>Discussion</p> <p>The DECISION study has been designed to test whether sorafenib improves PFS in patients with locally advanced or metastatic RAI-refractory DTC.</p> <p>Trial Registration</p> <p>ClinicalTrials.gov Identifier: <a href="http://www.clinicaltrials.gov/ct2/show/NCT00984282">NCT00984282</a>; EudraCT: 2009-012007-25.</p

Ecological expected utility and the mythical neural code

Neural spikes are an evolutionarily ancient innovation that remains nature’s unique mechanism for rapid, long distance information transfer. It is now known that neural spikes sub serve a wide variety of functions and essentially all of the basic questions about the communication role of spikes have been answered. Current efforts focus on the neural communication of probabilities and utility values involved in decision making. Significant progress is being made, but many framing issues remain. One basic problem is that the metaphor of a neural code suggests a communication network rather than a recurrent computational system like the real brain. We propose studying the various manifestations of neural spike signaling as adaptations that optimize a utility function called ecological expected utility

Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study

Aims/hypothesis Outcome data on individuals with diabetic foot ulcers are scarce, especially in those with peripheral arterial disease (PAD). We therefore examined the clinical characteristics that best predict poor outcome in a large population of diabetic foot ulcer patients and examined whether such predictors differ between patients with and without PAD. Methods Analyses were conducted within the EURODIALE Study, a prospective cohort study of 1,088 diabetic foot ulcer patients across 14 centres in Europe. Multiple logistic regression modelling was used to identify independent predictors of outcome (i.e. non-healing of the foot ulcer). Results After 1 year of follow-up, 23% of the patients had not healed. Independent baseline predictors of non-healing in the whole study population were older age, male sex, heart failure, the inability to stand or walk without help, end-stage renal disease, larger ulcer size, peripheral neuropathy and PAD. When analyses were performed according to PAD status, infection emerged as a specific predictor of non-healing in PAD patients only. Conclusions/Interpretation Predictors of healing differ between patients with and without PAD, suggesting that diabetic foot ulcers with or without concomitant PAD should be defined as two separate disease states. The observed negative impact of infection on healing that was confined to patients with PAD needs further investigation

Uniformisierung eines Typs von Wellenlaengenschieber-Lichtleitern fuer das ZEUS-Kalorimeter

SIGLEAvailable from Bonn Univ. (DE). Physikalisches Inst. / FIZ - Fachinformationszzentrum Karlsruhe / TIB - Technische InformationsbibliothekDEGerman

REVELIERIA GROEHNI — A NEW SPECIES OF MINUTE BROWN SCAVENGER BEETLES (COLEOPTERA, LATRIDIIDAE) FROM BALTIC AMBER

Based on a fossil specimen from Late Eocene Baltic amber, Revelieria groehni Sergi, Perkovsky et Reike, sp. n., a new species is described. It is the first fossil species of the genus Revelieria Perris, 1869. The new species clearly differs from extant R. californica and R. genei in the following characters: eyes more large and convex; antennal insertion located more close to eye; temples very short; metasternum longer; fore tibia evenly curved inwards.Из позднеэоценового балтийского янтаря описан Revelieria groehni Sergi, Perkovsky et Reike, sp. n. Это первый ископаемый вид рода Revelieria Perris, 1869. Новый вид отличается от современных R. californica и R. genei следующими признаками: глаза более крупные и выпуклые; усиковые впадины расположены ближе к глазу; виски очень короткие; заднегрудка длиннее; передняя голень равномерно изогнута внутрь